Exact Mass: 424.1706
Exact Mass Matches: 424.1706
Found 496 metabolites which its exact mass value is equals to given mass value 424.1706
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Clindamycin
Clindamycin is a semisynthetic lincosamide antibiotic that has largely replaced lincomycin due to an improved side effect profile. Clindamycin inhibits bacterial protein synthesis by binding to bacterial 50S ribosomal subunits. It may be bacteriostatic or bactericidal depending on the organism and drug concentration. Clindamycin, also known as cleocin or 7-CDL, belongs to the class of organic compounds known as proline and derivatives. Proline and derivatives are compounds containing proline or a derivative thereof resulting from reaction of proline at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom. Clindamycin is a drug. Clindamycin is a semisynthetic lincosamide antibiotic that has largely replaced lincomycin due to an improved side effect profile. Clindamycin is a very strong basic compound (based on its pKa). In humans, clindamycin is involved in clindamycin action pathway. Orally and parenterally administered clindamycin has been associated with severe colitis (pseudomembranous colitis) which may result in patient death. Use of the topical formulation of clindamycin results in absorption of the antibiotic from the skin surface. Clindamycin is a potentially toxic compound. Rapidly absorbed after oral administration with peak serum concentrations observed after about 45 minutes. Oral; topical; parenteral (intramuscular, intravenous). Systemic/vaginal clindamycin inhibits protein synthesis of bacteria by binding to the 50S ribosomal subunits of the bacteria. Clindamycin. CAS Common Chemistry. CAS, a division of the American Chemical Society, n.d. https://commonchemistry.cas.org/detail?cas_rn=18323-44-9 (retrieved 2024-06-28) (CAS RN: 18323-44-9). Licensed under the Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0).
N,N'-diacetylchitobiose
N,N-diacetylchitobiose, also known as (GlcNAc)2, is classified as a member of the Acylaminosugars. Acylaminosugars are organic compounds containing a sugar linked to a chain through N-acyl group. N,N-diacetylchitobiose is considered to be soluble (in water) and acidic. N,N-diacetylchitobiose may be a unique E.coli metabolite N,N'-Diacetylchitobiose is a dimer of β(1,4) linked N-acetyl-D glucosamine. N,N'-Diacetylchitobiose is the hydrolysate of chitin and can be used as alternative carbon source by?E. coli[1].
Trimethobenzamide hydrochloride
D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents C78272 - Agent Affecting Nervous System > C267 - Antiemetic Agent D005765 - Gastrointestinal Agents > D000932 - Antiemetics D002491 - Central Nervous System Agents Trimethobenzamide hydrochloride is a blocker of the D2 receptor. Trimethobenzamide is an antiemetic used to prevent nausea and vomiting.
Taraxinic acid glucosyl ester
Constituent of Taraxacum officinale (dandelion). Taraxinic acid glucosyl ester is found in many foods, some of which are coffee and coffee products, dandelion, tea, and alcoholic beverages. Taraxinic acid glucosyl ester is found in alcoholic beverages. Taraxinic acid glucosyl ester is a constituent of Taraxacum officinale (dandelion).
D-Cloprostenol
8-Acetylneosolaniol
Calix[4]arene
Methanone, ((2R,5R)-5-(((5-fluoro-2-pyridinyl)oxy)methyl)-2-methyl-1-piperidinyl)(5-fluoro-2-(2-pyrimidinyl)phenyl)-
Forsmann antigen
Galnac-1-4-glcnac
Lacdinac
N,N'-Diacetylchitobiose is a dimer of β(1,4) linked N-acetyl-D glucosamine. N,N'-Diacetylchitobiose is the hydrolysate of chitin and can be used as alternative carbon source by?E. coli[1].
SPIRADOLINE
Crepidiaside B
Crepidiaside b is a member of the class of compounds known as O-glycosyl compounds. O-glycosyl compounds are glycoside in which a sugar group is bonded through one carbon to another group via a O-glycosidic bond. Crepidiaside b is slightly soluble (in water) and a very weakly acidic compound (based on its pKa). Crepidiaside b can be found in chicory and endive, which makes crepidiaside b a potential biomarker for the consumption of these food products.
[3aR-(3aR*,5E,9Z,11aR*)]- 2,3,3a,4,7,8,11,11a-Octahydro-6-methyl-3-methylene-2-oxo-, beta-D-glucopyranosyl ester cyclodeca[b]furan-10-carboxylic acid
[4R-(4R*,5S*,6S*,7S*,10R*,11E)]- 3-[(Acetyloxy)methyl]-5,6,7,8,9,10-hexahydro-6,7-dihydroxy-5,6,10-trimethyl-4-(1-oxopropoxy)-7,10-epoxycyclodeca[b]furan-2(4H)-one
9-(3-Hydroxy-3-methylglutaroyloxy)-abscisic acid|beta-hydroxy-beta-methylglutarylhydroxyabscisic acid
15-glucopyranosyloxy-2-oxo-guaia-3,11(13)-dien-1beta,5alpha,6beta,7alpha,10alphaH-12,6-olide
11,13alpha-dihydroixerin Z|11beta,13-dihydroixerin Z
11beta-hydroxyleucodin 11-O-beta-D-glucopyranoside|11beta-hydroxyleucodin-11-O-beta-glucopyranoside|11beta-hydroxyleucodin-O-beta-D-glucopyranoside|11beta-hydroxyleukodin 11-O-beta-glucopyranoside|11??-Hydroxyleukodin 11-O-??-glucopyranoside
beta-hydroxy-beta-methylglutaryl ester of 8-hydroxyabscisic acid
10,11-dioxo-aspidofractinine-1,3-dicarboxylic acid dimethyl ester|10,11-Dioxo-pleiocarpin
8beta,9alpha-dihydroxy-5alpha,9betaH-lindan-4(15),7(13)-dien-8alpha,12-olide-8beta-O-beta-D-glucopyranoside|chloranthalactone E 8-O-beta-D-glucopyranoside
3alpha-acetoxy-5beta-(4-acetoxytigloyloxy)-7-acetoxycarvotanacetone
(-)-(7R,8R)-4,7,9,8,9-pentahydroxy-3,3,5-trimethoxy-8-O-4-neolignan|3-(4-{[(1R,2R)-1,3-dihydroxy-1-(4-hydroxy-3-methoxyphenyl)propan-2-yl]oxy}-3,5-dimethoxyphenyl)propane-1,2-diol|casearialignan D
2alpha-hydroperoxy-8-O-isobutyryl-9alpha-acetoxycumambrin B|2??-Hydroperoxy-8-O-isobutyryl-9??-acetoxycumambrin B
8alpha-(4-hydroxymethacryloyloxy)-10alpha-hydroxy-1,13-dimethoxy-hirsutinolide
(1R*,4R*,8S*,10R*)-1,4-epoxy-1-ethoxy-8,13-diacetoxy-10-hydroxy-germacra-5E,7(11)-dien-6,12-olide
O1-Me,8-propanoyl,13-Ac-1,4-Epoxy-1,8,10,13-tetrahydroxy-5,7(11)-germacradien-12,6-olide
C21H28O9_1-O-{[(3aS,6Z,10E,11aR)-10-Methyl-3-methylene-2-oxo-2,3,3a,4,5,8,9,11a-octahydrocyclodeca[b]furan-6-yl]carbonyl}-beta-D-glucopyranose
C21H28O9_2-Hydroxycyclohexyl 2-O-[(2E)-3-(4-hydroxyphenyl)-2-propenoyl]-beta-D-glucopyranoside
[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (3aS,6Z,10E,11aR)-10-methyl-3-methylidene-2-oxo-3a,4,5,8,9,11a-hexahydrocyclodeca[b]furan-6-carboxylate
2-oxapentacyclo[21.2.2.13,7.110,14.015,20]nonacosa-1(25),3,5,7(29),10(28),11,13,15(20),16,18,23,26-dodecaene-4,13,18-triol
CONFIDENCE Predicted
[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (3aS,6Z,10E,11aR)-10-methyl-3-methylidene-2-oxo-3a,4,5,8,9,11a-hexahydrocyclodeca[b]furan-6-carboxylate_major
[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (3aS,6Z,10E,11aR)-10-methyl-3-methylidene-2-oxo-3a,4,5,8,9,11a-hexahydrocyclodeca[b]furan-6-carboxylate_7.2\\%
[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (3aS,6Z,10E,11aR)-10-methyl-3-methylidene-2-oxo-3a,4,5,8,9,11a-hexahydrocyclodeca[b]furan-6-carboxylate_5.5\\%
[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (3aS,6Z,10E,11aR)-10-methyl-3-methylidene-2-oxo-3a,4,5,8,9,11a-hexahydrocyclodeca[b]furan-6-carboxylate_4.0\\%
Ala Phe Gly Met
Ala Phe Met Gly
Ala Gly Phe Met
Ala Gly Met Phe
Ala Met Phe Gly
Ala Met Gly Phe
Cys Phe Gly Val
Cys Phe Val Gly
Cys Gly Phe Val
Cys Gly Val Phe
Cys Thr Thr Thr
Cys Val Phe Gly
Cys Val Gly Phe
Asp Gly His Pro
Asp Gly Pro His
Asp His Gly Pro
Asp His Pro Gly
Asp Pro Gly His
Asp Pro His Gly
Phe Ala Gly Met
Phe Ala Met Gly
Phe Cys Gly Val
Phe Cys Val Gly
Phe Gly Ala Met
Phe Gly Cys Val
Phe Gly Met Ala
Phe Gly Val Cys
Phe Met Ala Gly
Phe Met Gly Ala
Phe Val Cys Gly
Phe Val Gly Cys
Gly Ala Phe Met
Gly Ala Met Phe
Gly Cys Phe Val
Gly Cys Val Phe
Gly Asp His Pro
Gly Asp Pro His
Gly Phe Ala Met
Gly Phe Cys Val
Gly Phe Met Ala
Gly Phe Val Cys
Gly His Asp Pro
Gly His Pro Asp
Gly Met Ala Phe
Gly Met Phe Ala
Gly Pro Asp His
Gly Pro His Asp
Gly Val Cys Phe
Gly Val Phe Cys
His Asp Gly Pro
His Asp Pro Gly
His Gly Asp Pro
His Gly Pro Asp
His Pro Asp Gly
His Pro Gly Asp
Met Ala Phe Gly
Met Ala Gly Phe
Met Phe Ala Gly
Met Phe Gly Ala
Met Gly Ala Phe
Met Gly Phe Ala
Met Ser Ser Thr
Met Ser Thr Ser
Met Thr Ser Ser
Pro Asp Gly His
Pro Asp His Gly
Pro Gly Asp His
Pro Gly His Asp
Pro His Asp Gly
Pro His Gly Asp
Ser Met Ser Thr
Ser Met Thr Ser
Ser Ser Met Thr
Ser Ser Thr Met
Ser Thr Met Ser
Ser Thr Ser Met
Thr Cys Thr Thr
Thr Met Ser Ser
Thr Ser Met Ser
Thr Ser Ser Met
Thr Thr Cys Thr
Thr Thr Thr Cys
Val Cys Phe Gly
Val Cys Gly Phe
Val Phe Cys Gly
Val Phe Gly Cys
Val Gly Cys Phe
Val Gly Phe Cys
(+)-5-trans Cloprostenol
(+)-15-epi Cloprostenol
Cloprostenol
D012102 - Reproductive Control Agents > D003270 - Contraceptive Agents D012102 - Reproductive Control Agents > D008186 - Luteolytic Agents
(+)-Cloprostenol
Taraxinic acid glucosyl ester
2-heptadecyl-4,5-dihydro-1H-imidazole-1-ethanol phosphate
10-[4-(1-naphthalenyl)phenyl]-9-anthracenyl]-Boronic acid[
10-[4-(2-naphthalenyl)phenyl]-9-anthracenyl]-Boronic acid
4-([trans(trans)]-4-butyl-[1,1-bicyclohexyl]-4-yl)-1-iodo-Benzene
[trans(trans)]-1-(4-Butyl[1,1-bicyclohexyl]-4-yl)-4-iodobenzene
[4-[9-(Naphthalen-2-yl)anthracen-10-yl]phenyl]boronic acid
2-[[4-[(2-cyanoethyl)(2-phenylethyl)amino]phenyl]azo]-5-nitrobenzonitrile
N,N-Diacetylchitobiose
The N,N-diacetylated derivative of chitobiose, but with no stereodesignation for the anomeric carbon atom. N,N'-Diacetylchitobiose is a dimer of β(1,4) linked N-acetyl-D glucosamine. N,N'-Diacetylchitobiose is the hydrolysate of chitin and can be used as alternative carbon source by?E. coli[1].
Anileridine hydrochloride
C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent
GlcNAc1-beta-3GalNAc
Ethyl 2-[2-[2-(4-methoxyanilino)-2-oxoethyl]-1-oxoisoquinolin-5-yl]oxypropanoate
beta-D-GlcpNAc-(1->6)-D-GalpNAc
An amino disaccharide consisting of N-acetyl-D-galactosamine having a N-acetyl-beta-D-glucosaminyl residue attached at the 6-position.
2-Acetamido-6-O-(2-acetamido-2-deoxy-a-D-galactopyranosyl)-2-deoxy-D-galactopyranose
2-Acetamido-4-O-(2-acetamido-2-deoxy-a-D-galactopyranosyl)-2-deoxy-D-galactopyranose
SPIRADOLINE
D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent D002491 - Central Nervous System Agents > D000700 - Analgesics D002317 - Cardiovascular Agents > D045283 - Natriuretic Agents D045283 - Natriuretic Agents > D004232 - Diuretics
12-(2-hydroxyethyl)-2-(1-methylethoxy)-13,14-dihydronaphtho[2,1-a]pyrrolo[3,4-c]carbazol-5(12H)-one
(4,11-Diacetyloxy-10-hydroxy-1,5-dimethylspiro[8-oxatricyclo[7.2.1.02,7]dodec-5-ene-12,2-oxirane]-2-yl)methyl acetate
[(2R,4S,10R,11S)-10,11-diacetyloxy-4-hydroxy-1,5-dimethylspiro[8-oxatricyclo[7.2.1.02,7]dodec-5-ene-12,2-oxirane]-2-yl]methyl acetate
2-(3,4-dichlorophenyl)-N-methyl-N-[7-(pyrrolidin-1-yl)-1-oxaspiro[4.5]decan-8-yl]acetamide
beta-D-GalpNAc-(1->4)-beta-D-GlcpNAc
beta-D-GalpNAc-(1->4)-D-GlcpNAc with beta configuration at the anomeric centre.
beta-D-GlcpNAc-(1->3)-alpha-D-GalpNAc
An amino disaccharide comprising an N-acetyl-beta-D-glucosamine residue linked (1->3) to an N-acetyl-beta-D-galactosamine residue at the reducing end.
beta-D-GlcpNAc-(1->6)-alpha-D-GalpNAc
beta-D-GlcpNAc-(1->6)-D-GalpNAc in which the anomeric configuration of the reducing-end GalNAc residue is alpha.
N-acetyl-beta-D-glucosaminyl-(1->4)-N-acetyl-alpha-D-glucosamine
N-[1-(3-methoxyphenyl)-3-(1-naphthalenylamino)-3-oxopropyl]benzamide
methyl 3-[[2-[4-(furan-2-carbonyl)piperazin-1-yl]acetyl]amino]-6-methyl-1H-indole-2-carboxylate
N-[5-ethyl-3-[(4-fluorophenyl)-(4-morpholinyl)methyl]-2-thiophenyl]benzamide
2-Acetamido-6-O-(2-acetamido-2-deoxy-beta-D-glucopyranosyl)-2-deoxy-D-glucopyranose
(2S,4R)-N-[(1S,2S)-2-chloro-1-[(3R,4S,5R,6R)-3,4,5-trihydroxy-6-(methylthio)-2-oxanyl]propyl]-1-methyl-4-propyl-2-pyrrolidinecarboxamide
N-acetyl-D-galactosaminyl-(1->3)-N-acetyl-D-galactosamine
beta-D-GalpNAc-(1->3)-alpha-D-GalpNAc
An amino disaccharide comprised of N-acetyl-alpha-D-galactosamine having an N-acetyl-D-galactosaminyl residue attached at the 3-position via a beta-linkage.
2-acetamido-4-O-(2-acetamido-2-deoxy-beta-D-galactopyranosyl)-2-deoxy-alpha-D-galactopyranose
1,3-benzodioxol-5-yl-[(1R,5S)-7-[4-[(E)-2-phenylethenyl]phenyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]methanone
N-[(2S,3R,6S)-2-(hydroxymethyl)-6-(2-oxo-2-piperidin-1-ylethyl)-3,6-dihydro-2H-pyran-3-yl]-2-methoxybenzenesulfonamide
N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-methoxybenzenesulfonamide
N-[(2R,3R,6R)-2-(hydroxymethyl)-6-(2-oxo-2-piperidin-1-ylethyl)-3,6-dihydro-2H-pyran-3-yl]-2-methoxybenzenesulfonamide
N-[(2R,3S,6S)-6-[2-[(2-chlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-4-oxanecarboxamide
2-[(1S,3R,4aR,9aS)-1-(hydroxymethyl)-6-(methanesulfonamido)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]-N-cyclopentylacetamide
N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-methoxybenzenesulfonamide
N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-methoxybenzenesulfonamide
N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-methoxybenzenesulfonamide
N-[(2S,3R,6S)-6-[2-[(2-chlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)oxan-3-yl]oxane-4-carboxamide
N-[(2S,3R,6R)-6-[2-[(2-chlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)oxan-3-yl]oxane-4-carboxamide
N-[(2S,3S,6S)-6-[2-[(2-chlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-4-oxanecarboxamide
2-[(1R,3R,4aR,9aS)-1-(hydroxymethyl)-6-(methanesulfonamido)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-cyclopentylacetamide
2-[(1R,3S,4aS,9aR)-1-(hydroxymethyl)-6-(methanesulfonamido)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]-N-cyclopentylacetamide
N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-methoxybenzenesulfonamide
N-[(2R,3S,6R)-6-[2-[(2-chlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-4-oxanecarboxamide
N-[(2R,3R,6R)-6-[2-[(2-chlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-4-oxanecarboxamide
2-[(1S,3S,4aS,9aR)-1-(hydroxymethyl)-6-(methanesulfonamido)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-cyclopentylacetamide
2-[(1S,3R,4aS,9aR)-1-(hydroxymethyl)-6-(methanesulfonamido)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-cyclopentylacetamide
[(1S,2aR,8bR)-4-[(3-fluorophenyl)-oxomethyl]-1-(hydroxymethyl)-1,2a,3,8b-tetrahydroazeto[2,3-c]quinolin-2-yl]-(4-oxanyl)methanone
[(1R,2aR,8bR)-4-[(3-fluorophenyl)-oxomethyl]-1-(hydroxymethyl)-1,2a,3,8b-tetrahydroazeto[2,3-c]quinolin-2-yl]-(4-oxanyl)methanone
N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-methoxybenzenesulfonamide
N-[(2S,3S,6R)-6-[2-[(2-chlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-4-oxanecarboxamide
N-[(2R,3R,6S)-6-[2-[(2-chlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-4-oxanecarboxamide
2-[(1R,3S,4aR,9aS)-1-(hydroxymethyl)-6-(methanesulfonamido)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-cyclopentylacetamide
2-[(1R,3R,4aS,9aR)-1-(hydroxymethyl)-6-(methanesulfonamido)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-cyclopentylacetamide
2-[(1S,3S,4aR,9aS)-1-(hydroxymethyl)-6-(methanesulfonamido)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-cyclopentylacetamide
[(1S,2aS,8bS)-4-[(3-fluorophenyl)-oxomethyl]-1-(hydroxymethyl)-1,2a,3,8b-tetrahydroazeto[2,3-c]quinolin-2-yl]-(4-oxanyl)methanone
[(1R,2aS,8bS)-4-[(3-fluorophenyl)-oxomethyl]-1-(hydroxymethyl)-1,2a,3,8b-tetrahydroazeto[2,3-c]quinolin-2-yl]-(4-oxanyl)methanone
2-acetamido-2-deoxy-D-gluco-hexopyranosyl-(1->3)-2-acetamido-2-deoxy-alpha-D-galacto-hexopyranose
[2-butyl-5-chloro-3-[[4-[2-(2,3-dihydro-1H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol
(3alpha)-3-Hydroxy-12,13-epoxytrichothec-9-ene-4,8,15-triyl triacetate
3-Hydroxy-12,13-epoxytrichothec-9-ene-4,8,15-triyl triacetate
[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (3aS,10Z,11aR)-10-methyl-3-methylidene-2-oxo-3a,4,5,8,9,11a-hexahydrocyclodeca[b]furan-6-carboxylate
(2S,4R)-N-[(1R)-2-chloro-1-[(2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide
platencin(1-)
A monocarboxylic acid anion that is the conjugate base of platencin resulting from the deprotonation of the carboxy group; major species at pH 7.3.
Cleocin
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D055231 - Lincosamides D004791 - Enzyme Inhibitors > D011500 - Protein Synthesis Inhibitors
beta-D-GalpNAc-(1->4)-D-GlcpNAc
An amino disaccharide consisting of N-acetylglucosamine having an N-acetylgalactosaminyl resiude attached at the 4-position via a beta-linkage.
N-acetyl-beta-D-glucosaminyl-(1->4)-N-acetyl-aldehydo-D-glucosamine
alpha-D-GalpNAc-(1->4)-beta-D-GlcpNAc
An alpha-D-GalpNAc-(1->4)-D-GlcpNAc in which the reducing end anomeric centre has beta-configuration.
D-GalpNAc-(1->3)-D-GalpNAc
A disaccharide composed of two 2-(acetylamino)-2-deoxy-D-galactopyranose units in (1->3) linkage.
2-Acetamido-2-deoxy-3-O-(2-acetamido-2-deoxy-B-D-glucopyranosyl)-D-galactopyranose
beta-D-GalpNAc-(1->4)-alpha-D-GalpNAc
An amino disaccharide comprised of N-acetyl-alpha-D-galactosamine having an N-acetyl-D-galactosaminyl residue attached at the 4-position via a beta-linkage. Important epitope forming part of the O-polysaccharides of some Gram-negative bacteria.
alpha-D-GalpNAc-(1->3)-D-GalpNAc
An amino disaccharide consisting of two N-acetyl-D-galactosamine units joined via an alpha-(1->3)-linkage.
alpha-D-GalpNAc-(1->4)-D-GlcpNAc
An amino disaccharide consisting of N-acetyl-D-glucosamine having an N-acetyl-alpha-D-galactosminyl resiude attached at the 4-position.
alpha-D-GalNpAc-(1->3)-beta-D-GalpNAc
An alpha-D-GalpNAc-(1->3)-D-GalpNAc having beta-configuration at the reducing end anomeric centre.
clindamycin
A carbohydrate-containing antibiotic that is the semisynthetic derivative of lincomycin, a natural antibiotic.
N-acetyl-beta-D-glucosaminyl-(1->4)-N-acetyl-beta-D-glucosamine
An N,N-diacetylchitobiose having beta-configuration at the reducing end anomeric centre.
(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (3as,11ar)-10-methyl-3-methylidene-2-oxo-3ah,4h,5h,8h,9h,11ah-cyclodeca[b]furan-6-carboxylate
5-hydroxy-3,6,9-trimethylidene-8-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-octahydroazuleno[4,5-b]furan-2-one
methyl 15-hydroxy-16-oxo-8,10-dioxa-13,19-diazaoctacyclo[12.8.2.1¹,¹⁵.0²,¹⁹.0³,¹⁴.0³,¹⁷.0⁴,¹².0⁷,¹¹]pentacosa-4(12),5,7(11)-triene-13-carboxylate
[8-(acetyloxy)-11-ethoxy-10-hydroxy-1,10-dimethyl-5-oxo-4,14-dioxatricyclo[9.2.1.0³,⁷]tetradeca-2,6-dien-6-yl]methyl acetate
(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (3ar,11as)-6-methyl-3-methylidene-2-oxo-3ah,4h,7h,8h,11h,11ah-cyclodeca[b]furan-10-carboxylate
butyl (1s,3r,4r,5r)-1,3,4-trihydroxy-5-{[(2e)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoyl]oxy}cyclohexane-1-carboxylate
2-oxapentacyclo[22.2.2.1³,⁷.0¹⁰,¹⁵.0¹⁶,²¹]nonacosa-1(26),3(29),4,6,10,12,14,16,18,20,24,27-dodecaene-4,12,17-triol
15-oxapentacyclo[20.2.2.2¹⁶,¹⁹.1¹⁰,¹⁴.0²,⁷]nonacosa-1(25),2,4,6,10,12,14(29),16,18,22(26),23,27-dodecaene-5,13,24-triol
(1's,2s,2'r,3's,4z,5'r,7'r,8's,9'r,12's)-2'-hydroxy-12'-(2-hydroxypropan-2-yl)-8'-methoxy-4-(1-methoxyethylidene)-7'-methyl-4',10'-dioxaspiro[oxolane-2,6'-tetracyclo[7.2.1.0²,⁷.0³,⁵]dodecane]-5,11'-dione
4,5-dihydroxy-6-[(2-hydroxycyclohexyl)oxy]-2-(hydroxymethyl)oxan-3-yl 3-(4-hydroxyphenyl)prop-2-enoate
[(2r,3s,4s,5r,6r)-6-[(3z)-hex-3-en-1-yloxy]-3,4,5-trihydroxyoxan-2-yl]methyl (2e)-3-(3,4-dihydroxyphenyl)prop-2-enoate
2,15-dioxapentacyclo[22.2.2.1³,⁷.1¹⁰,¹⁴.0¹⁶,²¹]triaconta-1(26),3(30),4,6,10(29),11,13,16,18,20,24,27-dodecaene-4,17-diol
(3as,5r,9ar,9bs)-5-hydroxy-6-methyl-3-methylidene-9-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)-3ah,4h,5h,7h,9ah,9bh-azuleno[4,5-b]furan-2-one
5-(acetyloxy)-9-hydroperoxy-6-hydroxy-6,9-dimethyl-3-methylidene-2-oxo-3ah,4h,5h,6ah,9ah,9bh-azuleno[4,5-b]furan-4-yl 2-methylpropanoate
(2s,4r)-n-{2-chloro-1-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(methylsulfanyl)oxan-2-yl]propyl}-1-methyl-4-propylpyrrolidine-2-carboximidic acid
2,16-dioxapentacyclo[23.2.2.1³,⁷.0¹⁰,¹⁵.0¹⁷,²²]triaconta-1(27),3(30),4,6,10,12,14,17,19,21,25,28-dodecaene-4,18-diol
(3r,3ar,9as,9br)-3,6,9-trimethyl-3-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-3ah,4h,5h,9ah,9bh-azuleno[4,5-b]furan-2,7-dione
(1'r,2s,2's,3'r,4's,8'r,9'r)-9'-(acetyloxy)-12'-[(acetyloxy)methyl]-3'-(hydroxymethyl)-10'-oxaspiro[oxirane-2,7'-tricyclo[6.4.0.0²,⁴]dodecan]-11'-en-3'-ylmethyl acetate
(3ar,4s,9ar,9br)-4-hydroxy-6-methyl-3-methylidene-9-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)-3ah,4h,5h,7h,9ah,9bh-azuleno[4,5-b]furan-2-one
3,6-dimethyl-9-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)-3h,3ah,4h,5h,6h,6ah-azuleno[4,5-b]furan-2,7-dione
14-oxapentacyclo[20.2.2.2¹⁰,¹³.1¹⁵,¹⁹.0²,⁷]nonacosa-1(25),2,4,6,10,12,15(27),16,18,22(26),23,28-dodecaene-3,16,24-triol
(3ar,4s,9as,9br)-4-hydroxy-6-methyl-3-methylidene-8-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)-3ah,4h,5h,9h,9ah,9bh-azuleno[4,5-b]furan-2-one
(1's,2s,2'r,4's,7'r,9'r,10'r,11's)-4',11'-bis(acetyloxy)-10'-hydroxy-1',5'-dimethyl-8'-oxaspiro[oxirane-2,12'-tricyclo[7.2.1.0²,⁷]dodecan]-5'-en-2'-ylmethyl acetate
1(10),4,11(13)-germacratrien-12,6-olid-14-oic acid; (1(10)z,4e,6α)-form,beta-d-glucopyranosyl ester
{"Ingredient_id": "HBIN000219","Ingredient_name": "1(10),4,11(13)-germacratrien-12,6-olid-14-oic acid; (1(10)z,4e,6\u03b1)-form,beta-d-glucopyranosyl ester","Alias": "NA","Ingredient_formula": "C21H28O9","Ingredient_Smile": "NA","Ingredient_weight": "0","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "9727","PubChem_id": "NA","DrugBank_id": "NA"}